Literature DB >> 8510707

Prognosis of untreated patients with idiopathic membranous nephropathy.

A Schieppati1, L Mosconi, A Perna, G Mecca, T Bertani, S Garattini, G Remuzzi.   

Abstract

BACKGROUND: Defining the most appropriate treatment for patients with idiopathic membranous nephropathy is a matter of controversy. The course of the disorder is often benign, and the immunosuppressive regimens used in some patients have uncertain benefits and substantial risks. We studied the natural history of idiopathic membranous nephropathy in patients who received only symptomatic therapy.
METHODS: We prospectively studied 100 consecutive patients (68 men and 32 women; mean [+/- SD] age, 51 +/- 17 years) with biopsy-proved idiopathic membranous nephropathy. The patients received diuretic or antihypertensive drugs as needed, but no glucocorticoid or immunosuppressive drugs. We examined the patients and measured their urinary protein excretion and serum creatinine concentrations every 6 months for a mean of 52 months.
RESULTS: Twenty-four (65 percent) of the 37 patients followed for at least five years had complete or partial remission of proteinuria; in 6 others (16 percent), end-stage renal disease developed, and they required dialysis. As calculated by the Kaplan-Meier method, the estimated probability (+/- the standard error of the estimate) of retaining adequate kidney function was 88 +/- 5 percent after five years and 73 +/- 7 percent after eight years. The prognosis was poorer in men and in patients over 50 years of age, but not in patients with the nephrotic syndrome, hypertension, or hypercholesterolemia.
CONCLUSIONS: Most untreated patients with idiopathic membranous nephropathy maintain renal function for prolonged periods and are likely to have spontaneous remission. These results do not support the use of glucocorticoids and immunosuppressive drugs in patients with idiopathic membranous nephropathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510707     DOI: 10.1056/NEJM199307083290203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  85 in total

1.  Melanocortin 1 receptor agonists reduce proteinuria.

Authors:  Annika Lindskog; Kerstin Ebefors; Martin E Johansson; Bergur Stefánsson; Anna Granqvist; Margret Arnadottir; Anna-Lena Berg; Jenny Nyström; Börje Haraldsson
Journal:  J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 10.121

2.  Treatment of progressive renal failure and nephrotic syndrome with azathioprine and prednisolone.

Authors:  L R Baker; B Tucker; I C Macdougall; R Oommen
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

3.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.

Authors:  Elion Hoxha; Sigrid Harendza; Hans Pinnschmidt; Ulf Panzer; Rolf A K Stahl
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-29       Impact factor: 8.237

4.  Long-term outcomes of initial therapy for idiopathic membranous nephropathy.

Authors:  Masayo Sato; Takashi Takei; Takahito Moriyama; Mitsuyo Itabashi; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2016-12-20       Impact factor: 2.801

5.  Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy.

Authors:  Ji Zhang; Min Pan; JianNa Zhang; XiaoHan You; Dou Li; Fan Lin; GuoYuan Lu
Journal:  Int Urol Nephrol       Date:  2019-08-28       Impact factor: 2.370

Review 6.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

7.  Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function.

Authors:  Yizhi Chen; Li Tang; Zhe Feng; Xueying Cao; Xuefeng Sun; Moyan Liu; Shuwen Liu; Xueguang Zhang; Ping Li; Ribao Wei; Qiang Qiu; Guangyan Cai; Xiangmei Chen
Journal:  J Nephrol       Date:  2014-02-13       Impact factor: 3.902

8.  Membranous Nephropathy: Quantifying Remission Duration on Outcome.

Authors:  Daniel C Cattran; Esther D Kim; Heather Reich; Michelle Hladunewich; S Joseph Kim
Journal:  J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 10.121

9.  Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy.

Authors:  A Kattah; R Ayalon; L H Beck; S Sethi; D G Sandor; F G Cosio; M J Gandhi; E C Lorenz; D J Salant; F C Fervenza
Journal:  Am J Transplant       Date:  2015-03-12       Impact factor: 8.086

Review 10.  Rituximab therapy for membranous nephropathy: a systematic review.

Authors:  Andrew S Bomback; Vimal K Derebail; Julie G McGregor; Abhijit V Kshirsagar; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-11       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.